Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors-Reference-Cited by-同舟云学术

Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors

Published:2013-07-12 Issue:9 Volume:53 Page:955-961
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Denton Cathrine L.¹,Minthorn Elisabeth²,Carson Stanley W.¹,Young Graeme C.³,Richards-Peterson Lauren E.⁴,Botbyl Jeffrey⁵,Han Chao⁶,Morrison Royce A.⁷,Blackman Samuel C.⁸,Ouellet Daniele¹

Affiliation:

1. GlaxoSmithKline; Research Triangle Park NC USA

2. GlaxoSmithKline; Collegeville PA USA

3. GlaxoSmithKline; Ware UK

4. GlaxoSmithKline; King of Prussia PA USA

5. Provonix; Mullica Hill NJ USA

6. Biologics Clinical Pharmacology; Janssen R&D; Spring House PA USA

7. Comprehensive Clinical Development; Tacoma WA USA

8. Translational Medicine; Seattle Genetics, Inc.; Bothell WA USA

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.127/fullpdf

Reference14 articles.

1. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial;Falchook;Lancet.,2012

2. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet.,2012

3. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma;Trefzer;Pigment Cell Melanoma Res.,2011

4. Characterization of the absorption, distribution, metabolism and elimination of a single oral 14C labeled dose of dabrafenib in subjects with BRAF V600-mutation positive solid tumors;Nebot;Clin Pharmacol Ther.,2013

5. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf 2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of a Low‐Fat Low‐Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open‐Label, 2‐Part Study in Healthy Participants;Clinical Pharmacology in Drug Development;2023-01-20

2. Dynamic Changes in Gastrointestinal Fluid Characteristics after Food Ingestion Are Important for Quantitatively Predicting the In Vivo Performance of Oral Solid Dosage Forms in Humans in the Fed State;Molecular Pharmaceutics;2022-11-14

3. Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling;Drug Metabolism and Disposition;2022-09-24

4. Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination;Clinical Pharmacology in Drug Development;2021-10-28

5. Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate);Clinical Pharmacology in Drug Development;2021-05